OptimizeRx Boards $10M Share Buyback After Fiscal 2025 EBITDA Doubles
OptimizeRx reported Q4 revenue of $32.2 M and adjusted EBITDA of $12.0 M, driving fiscal 2025 revenue to $109.4 M and adjusted EBITDA to $24.3 M while operating cash flow reached $18.7 M. The board authorized a $10 M share repurchase and set 2026 guidance at $109–114 M revenue and $21–25 M adjusted EBITDA despite early-year contracting softness.
1. Q4 and Fiscal 2025 Results
OptimizeRx generated Q4 revenue of $32.2 million and adjusted EBITDA of $12.0 million, lifting fiscal 2025 revenue to $109.4 million and adjusted EBITDA to $24.3 million. Non-GAAP net income was $9.9 million ($0.51 per share), operating cash flow reached $18.7 million and cash balances rose to $23.4 million.
2. Updated 2026 Outlook and Contracting Headwinds
Management set 2026 revenue guidance at $109–114 million and adjusted EBITDA at $21–25 million, reflecting early-year softness in contracted revenue from a market shift away from managed services and shortened contract durations tied to MFN pricing. Excluding managed services, contracted revenue is running about 15–20% behind historical pacing.
3. Capital Allocation and Share Repurchase
The board authorized a $10 million share repurchase program and prioritized debt repayment, having paid down $8.0 million in principal to leave current debt at $26.3 million. Excess cash will fuel share buybacks or additional debt reduction based on market conditions.
4. Strategic Execution and AI Commentary
Management highlighted margin expansion to 74.8% in Q4 driven by favorable product and partner mix and noted that margins may normalize to mid-60% levels in 2026. Growth among mid-tier and long-tail life sciences clients exceeded expectations, and AI was cited as a potential commercial tailwind.